Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2016-01-08 Capital/Financing Update
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Share buybacks / Liquidity contracts Information related to liquidity contracts
Capital/Financing Update Classification · 1% confidence The document is titled "HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT AT 31 DECEMBER 2015" and provides specific figures related to a liquidity contract (shares and cash balance) as of a specific date (December 31, 2015), comparing it to a previous date (June 30, 2015). This is a periodic disclosure related to market making or liquidity provision, which is a specific financial/regulatory activity. It is not a full Annual Report (10-K), a general Earnings Release (ER), or a comprehensive Interim Report (IR) covering all operations. It is a specific disclosure about a financial arrangement. Given the options, this type of specific, periodic financial disclosure that isn't a standard earnings report or annual report fits best under a specialized financial category. Since it details the status of a financial instrument/contract periodically, and it is not explicitly covered by other codes like DIV, NAV, or CAP, it is most closely related to specific financial updates. However, looking closely at the definitions, none perfectly capture a 'Liquidity Contract Report'. It is a periodic financial update. If it were a general update on financing or capital structure, CAP might apply, but this is very specific to liquidity management. Given the context of financial reporting, and the fact that it is a periodic report on a specific financial arrangement, it is a specialized disclosure. Since it is a report detailing specific financial metrics periodically, and not just an announcement of a report (RPA), it should be classified as a specific financial report. Since it is a half-year report, it shares characteristics with IR, but IR is defined as a comprehensive report. This document is very short and focused. Given the available codes, and recognizing this as a specific financial disclosure, it is closest to a specialized financial update. If we must choose from the list, and recognizing it is a periodic financial disclosure, it is not a standard 10-K or IR. It is a specific financial disclosure. In the absence of a 'Liquidity Report' code, and noting its periodic nature, it is a specialized financial disclosure. Since it is a report detailing financial status periodically, and not a general announcement, I will check if it fits 'IR' (Interim Report). It is a 'Half-Year Report', which aligns with 'Interim Report'. Although it is focused only on liquidity, it is a formal report for a half-year period. I will classify it as IR, as it is a half-year financial report, even if narrow in scope. If it were purely an announcement of the contract status, RNS might apply, but this reads like the report itself. I will assign IR.
2016-01-08 English
ABIVAX schliet Patientenrekrutierung fur ABX464 Phase IIa HIV-Studie ab
Regulatory Filings Classification · 1% confidence The document is a press release dated December 21, 2015, announcing that ABIVAX has completed patient recruitment for its ABX464 Phase IIa HIV study and that preliminary data will be released in January. It details the study design (Phase IIa, dose-finding, HIV-infected patients, monotherapy) and mentions the company's pipeline and contact information. This type of announcement, focusing on clinical trial milestones and upcoming data releases, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement about clinical progress rather than a comprehensive financial report (like 10-K or IR) or a general regulatory filing fallback, and it precedes the actual results announcement, 'ER' (Earnings Release, often used broadly for period results announcements) or 'RNS' (Regulatory Filing) are candidates. Given the focus on clinical trial progress and upcoming data, it functions as a key corporate update. However, since it is not a formal financial results summary (which would be an ER), and it is a specific corporate news item distributed via DGAP, the most appropriate general category for specific, non-standardized corporate news is 'RNS' (Regulatory Filings/General Announcements). If 'ER' is strictly for financial results, 'RNS' is the better fit for a clinical trial update announcement.
2015-12-21 German
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated December 21, 2015, announcing the finalization of patient recruitment for a Phase IIa clinical study (ABX464-003) for an HIV treatment. It details the study design, expected preliminary data release (January 2016), and provides context on the disease and the company's pipeline. This type of announcement, focusing on clinical trial progress and upcoming data releases, is characteristic of an Earnings Release (ER) or a general press release related to operational milestones. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, and it announces key operational news, it best fits the 'Earnings Release' category, which often encompasses significant operational updates outside of formal quarterly/annual reports, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure. Given the content focuses on clinical trial progress and upcoming data, ER is a strong fit for a major operational update, although RNS is a possibility for non-US filings. However, ER is used for key periodic announcements. Since this is a specific operational update rather than a formal financial results summary, and it's a press release format, I will classify it as a general announcement that doesn't fit the specific financial/governance codes. Given the options, and that it's a press release about a clinical milestone, it is most closely aligned with an operational update often bundled with ERs, but since it's not explicitly 'earnings', RNS (Regulatory Filings/Miscellaneous Announcement) is the safest fallback for a non-standard announcement, or ER if we interpret 'Earnings Release' broadly to include major operational news releases. Given the structure and purpose (announcing a milestone and upcoming data), it functions like a significant operational update often released around earnings periods. I will lean towards ER as it is a major operational announcement, but RNS is also plausible. Let's re-evaluate: It is a press release announcing a clinical trial milestone. This is not a formal financial report (10-K, IR), nor a transcript (CT), nor a management discussion (MDA). It is a specific operational update. In many databases, such press releases fall under general regulatory announcements or operational updates. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a clinical update, it doesn't perfectly match. 'RNS' (Regulatory Filings/Miscellaneous) is the best fit for a significant, non-standard press release announcement.
2015-12-21 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated December 21st, 2015, announcing the completion of patient recruitment for a Phase IIa clinical study (ABX464-003) and stating that preliminary data will be reported in January 2016. This type of announcement, detailing clinical trial progress and upcoming data releases, does not fit the definitions for formal financial reports (10-K, IR, ER), governance documents (CGR, DEF 14A), or specific transaction reports (DIV, SHA, POS). It is a general corporate update related to product development. Since it is a press release announcing a corporate event and future data release, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory/corporate announcement, or potentially a general 'Investor Presentation' (IP) if it were a presentation, but it reads like a news release. Given the options, RNS is the most appropriate fallback for a non-standard, time-sensitive corporate update that isn't a core financial filing or a specific transaction notice.
2015-12-21 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 1% confidence The document provides information regarding the total number of voting rights and shares ('Informations relatives au nombre total de droits de vote et d'actions') as required by French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16). This type of mandatory disclosure, detailing the capital structure and voting power as of a specific date (30/11/2015), is typically associated with regulatory reporting concerning share ownership thresholds or capital changes. While it touches upon capital structure, it is not a formal announcement of a dividend (DIV), a share issue (SHA), or a major shareholding notification (MRQ) in the typical sense of crossing a threshold. It is a routine regulatory disclosure about the current voting rights base. Given the options, this specific type of mandatory capital/voting rights disclosure, which is often filed periodically or upon request by regulators, fits best under the general 'Regulatory Filings' (RNS) category as a specific regulatory update that doesn't match the more specific financial or corporate action codes. It is too detailed for a simple 'Report Publication Announcement' (RPA) but lacks the context of a full financial report (10-K, IR) or a specific transaction (SHA, POS).
2015-12-10 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is titled '2016 Financial Calendar' and explicitly announces the schedule for future financial publications, including the '2016 Full-year Results', 'Publication of the 2016 Financial Annual Report', and '2016 Half-year Results'. It does not contain the actual content of these reports but rather announces *when* they will be published. According to Rule #2 (The 'MENU VS MEAL' Rule), a document announcing the publication of reports, especially when short, should be classified as a Report Publication Announcement (RPA).
2015-12-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.